TARDBP and neuroblastoma: This is a significant consideration in CNS treatment, as deleting Hsp90 in human neuroblastoma cells leads to a significant increase in phosphorylated TDP-43 aggregates, suggesting the role of Hsp90 in the degradation of the phosphorylated aggregate [68].